A remedy that reduces the possibility of death in one of the types of lung cancer

The results of a clinical study concluded on Sunday that one pill reduced the risk of death caused by one of the kinds of lung cancer, as it is one of the deadliest species with about 1.8 million deaths from all over the world. The results were announced in the most prominent annual conference for cancer specialists hosted by the ‘American Association for Clinical Oncology’ in Chicago, as it indicated that the patient’s eating for one pill of ‘Ozimirinib’ was developed, which was developed by the “Astrazinica” drug, called a certain type of lung cancer, called ” Cancer ”, which shows a certain type of mutation. These mutations affect 10% to 25% of lung cancer patients in the United States and Europe, and 30 to 40% in Asia. “The data is astounding”, and notes that the drug helps to “prevent the spread of the disease to the brain, liver and bones,” which indicates the possibility of surgery for a third of lung cancer cases, not -diagnosed with infection. He added that the doctors had not all adopted the treatment, and that they had been waiting for the information related to the survival rate in the world, which was shown on Sunday. He emphasizes the need to “investigate patients to see if they are showing the surge of human growth receptors, or it is difficult to subject it to this new treatment,” explains that “Osiminib,” which targets the future of the human growth factor, causes side effects, such as extreme fatigue, redness of the skin or diarrhea. A licensed treatment and the clinical experiment included approximately 680 participants in the early stage of the disease (Stages 1B to 3 A) in more than 20 countries, as the start of patients after surgery was eradicated, and half of the patients were treated daily, while the other half took a false medicine. It appeared that those who did the treatment decreased by the risk of death by 51% compared to patients who took the imaginary medicine, and after 5 years, 88% of patients who took the treatment for survival remained, compared to 7% of those who took a false agent. “It is difficult to indicate how important these results are. He added:” In the early stages, we entered the era of special treatments for patients, and the page of one treatment should be folded for everyone, ie chemotherapy. “” Astrazzinica “reported that the treatment of” Osimirinib “(sold under the name Tajreso), mainly in the dozen of countries, and it was to about 700,000 people, it was in the dozen of countries, and it was to about 700,000,000 people. Wanted to say the time they lived without repeating cancer.